Bloodstream Infection

Staphylococcus aureus bloodstream infection is one of the most serious bacterial infections worldwide. In Australia, it is estimated that approximately 5,000 infections occur per year (~10-20/100,000 population) with all patients being hospitalised and requiring a minimum of two weeks intravenous antibiotics.

Professor Steven Tong and Professor Josh Davis are leading the innovative Staphylococcus aureus bacteraemia Network Adaptive Platform Trial (SNAP) innovative trial to evaluate a range of interventions with the aim of improving outcomes for patients with Staphylococcus aureus bacteraemia (AKA bloodstream infections). The trial, world leading in terms of size, methods used, and the global collaborative network involved, aims to recruit 7,000 children and adults across more than 100 hospitals in six countries, including Australia, New Zealand and Canada. There are over 70 investigators contributing to the design and running of SNAP, many of whom are ASID members, in addition to site investigators. There is now a Youth (SNAP-PY) trial, which for the first time will enrol children alongside adults as part of the wider randomised controlled SNAP trial.